enVVeno Medical Corporation (NVNO)
NASDAQ: NVNO · Real-Time Price · USD
3.830
+0.350 (10.06%)
At close: Jun 6, 2025, 4:00 PM
3.831
+0.001 (0.04%)
After-hours: Jun 6, 2025, 7:51 PM EDT
enVVeno Medical Employees
enVVeno Medical had 37 employees as of December 31, 2024. The number of employees increased by 6 or 19.35% compared to the previous year.
Employees
37
Change (1Y)
6
Growth (1Y)
19.35%
Revenue / Employee
n/a
Profits / Employee
-$576,486
Market Cap
67.16M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
NVNO News
- 1 day ago - Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting - Accesswire
- 19 days ago - enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer - Accesswire
- 25 days ago - Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery - Accesswire
- 5 weeks ago - enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24 - Accesswire
- 6 weeks ago - VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium - Accesswire
- 7 weeks ago - enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment - Accesswire
- 2 months ago - The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium - Accesswire
- 3 months ago - enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25 - Accesswire